Jun 30, 2024

CVS Health Q2 2024 Earnings Report

Reported an increase in total revenues but a decrease in operating income and adjusted EPS due to challenges in the Health Care Benefits segment.

Key Takeaways

CVS Health reported a 2.6% increase in total revenues for the second quarter of 2024, reaching $91.2 billion. However, GAAP diluted EPS decreased to $1.41, and Adjusted EPS decreased to $1.83, primarily due to declines in the Health Care Benefits segment. The company has revised its full-year 2024 guidance to reflect continued pressure in the Health Care Benefits segment, partially offset by strong performance in the Health Services and Pharmacy & Consumer Wellness segments.

Total revenues increased by 2.6% to $91.2 billion compared to the prior year.

GAAP diluted EPS was $1.41, a decrease from $1.48 in the prior year.

Adjusted EPS was $1.83, a decrease from $2.21 in the prior year.

Revised full-year 2024 guidance reflects challenges in the Health Care Benefits segment.

Total Revenue
$91.3B
Previous year: $88.9B
+2.7%
EPS
$1.83
Previous year: $2.21
-17.2%
Medical membership
27M
Previous year: 25.63M
+5.3%
Gross Profit
$13.4B
Previous year: $13.6B
-1.6%
Cash and Equivalents
$16.3B
Previous year: $13.8B
+18.2%
Free Cash Flow
$2.45B
Previous year: $5.32B
-53.9%
Total Assets
$252B
Previous year: $250B
+1.0%

CVS Health

CVS Health

CVS Health Revenue by Segment

Forward Guidance

The Company revised its full-year 2024 GAAP diluted EPS guidance to a range of $4.95 to $5.20 from at least $5.64 and revised its full-year 2024 Adjusted EPS guidance to a range of $6.40 to $6.65 from at least $7.00. The Company also revised its full-year 2024 cash flow from operations guidance to approximately $9.0 billion from at least $10.5 billion. The Company’s guidance revision reflects continued pressure in the Health Care Benefits segment, partially offset by strong performance in the Health Services and Pharmacy & Consumer Wellness segments.

Positive Outlook

  • Strong performance in Health Services segment
  • Strong performance in Pharmacy & Consumer Wellness segment
  • Focus on innovation to improve patient outcomes
  • Acceleration of transparent pharmacy reimbursement models
  • Increasing the use of biosimilars

Challenges Ahead

  • Continued pressure in the Health Care Benefits segment
  • Revised GAAP diluted EPS guidance to a range of $4.95 to $5.20 from at least $5.64
  • Revised Adjusted EPS guidance to a range of $6.40 to $6.65 from at least $7.00
  • Revised cash flow from operations guidance to approximately $9.0 billion from at least $10.5 billion
  • Decline in Health Care Benefits segment’s operating results due to utilization pressure and unfavorable impact of Medicare Advantage star ratings

Revenue & Expenses

Visualization of income flow from segment revenue to net income